MARKET

LCTX

LCTX

Lineage Cell The
AMEX
1.300
-0.110
-7.80%
After Hours: 1.329 +0.029 +2.20% 19:57 04/12 EDT
OPEN
1.410
PREV CLOSE
1.410
HIGH
1.430
LOW
1.290
VOLUME
1.05M
TURNOVER
0
52 WEEK HIGH
1.610
52 WEEK LOW
0.8414
MARKET CAP
245.09M
P/E (TTM)
-10.4502
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at LCTX last week (0401-0405)?
Weekly Report · 6d ago
LINEAGE ANNOUNCES APPOINTMENT OF CHARLOTTE HUBBERT, PH.D., AS VICE PRESIDENT OF CORPORATE DEVELOPMENT
Reuters · 04/01 12:00
Weekly Report: what happened at LCTX last week (0325-0329)?
Weekly Report · 04/01 11:27
These 2 ‘Strong Buy’ Penny Stocks Could Go Boom, Say Analysts
TipRanks · 03/28 14:30
Weekly Report: what happened at LCTX last week (0318-0322)?
Weekly Report · 03/25 11:31
Lineage Cell Therapeutics Inc May Offer And Sell Common Shares Of Up To $40M From Time To Time Through Or To B. Riley
Benzinga · 03/22 20:36
Lineage Cell Therapeutics Entered Into Sales Agreement With B. Riley Securities; Effective As Of March 18 Controlled Equity Offering Sales Agreement Between Co And Cantor Fitzgerald & Co. Was Terminated; On March 12 Received Written Correspondence From U.S. FDA Regarding Its Ind As Amended For OPC1; Per Correspondence, FDA Advised That Company Not Initiate Proposed Clinical Study Until It Has Received FDA Feedback; FDA Anticipates Providing Feedback By April 26, 2024
Benzinga · 03/22 20:29
Optimistic Buy Rating for Lineage Cell Therapeutics Ahead of OpRegen Study Data Release
TipRanks · 03/19 05:46
More
About LCTX
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, the Company designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.

Webull offers Lineage Cell Therapeutics Inc stock information, including AMEX: LCTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LCTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LCTX stock methods without spending real money on the virtual paper trading platform.